1Globe Biomedical researches immune response to medical implant rejection

CENTRAL DISTRICT, Hong Kong - Oct. 29, 2020 - PRLog -- 1Globe Biomedical's research team have determined that the chemical composition of polymer materials can be changed to create materials that can control the response of the body's immune system.

1Globe Biomedical's invaluable research could assist future applications in the development for the fight against the rejection of medical implants which could be artificial joints, dental implants and vascular implants.

1Globe Biomedical's Chief Medical Officer commented on the medical implant research saying "The world of medicine and medical research is ever evolving and we are developing new ways to create materials that can be safely inserted inside the body without any rejection from the body's immune system. We are constantly exploring and testing materials that can control the immune response."

1Globe Biomedical's Chief Medical Officer also added "The implantation of biomaterials in the body generally triggers a reaction which can sometimes include responses such as inflammation, foreign body reaction and fibrous capsule development.  We will use state of the art screening technology to examine how the properties of the materials can be used to design immune‐instructive surfaces for potential use in implants being artificial joints, dental implants and specific other biomaterials to restore function or completely replace diseased or damaged tissues."

About Us - 1Globe Biomedical

1Globe Biomedical is a clinical stage biotechnology company pioneering the development of receptor T (1BioCARs™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of "off-the-shelf" receptor T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.

http://1globe-biomedical.com/about-us/history/index.html